

*The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ESSEX BIO-TECHNOLOGY LIMITED**

**億勝生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 8151)**

### **ANNOUNCEMENT**

This announcement is made at the request of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”). The board of directors (the “Board”) of Essex Bio-Technology Limited (the “Company”) has noted the increase in the price and the trading volume of the shares of the Company today and wishes to state that, save as disclosed below, the Board is not aware of any reasons for such increases.

To facilitate the business development plan of the Company and its subsidiaries (the “Group”), the Group intends to acquire certain piece(s) of land(s) in the People’s Republic of China (the “PRC”) for its business operation in the near future. The Group is currently considering submitting a bid to acquire a piece of land in the PRC, and the proposed acquisition may or may not proceed. In any event, the Group may or may not succeed in the bidding of such land, and the proposed acquisition therefore may or may not materialise. If the proposed acquisition materialises, it may constitute a discloseable transaction for the Company under the GEM Listing Rules. Further announcement will be made by the Company in compliance with the GEM Listing Rules as and when appropriate.

Save as the aforesaid, the Board confirms that there are no negotiations or agreements relating to intended acquisitions or realizations which are discloseable under Chapters 19 and 20 of the Rules Governing the Listing of Securities on the Growth Enterprise Market of the Stock Exchange (the “GEM Listing Rules”), neither is the Board aware of any matter discloseable under the general obligation imposed by Rule 17.10 of the GEM Listing Rules, which is or may be of a price-sensitive nature.

Made by the order of the Board, the directors of which collectively and individually accept responsibility for the accuracy of this announcement.

By Order of the Board  
**Essex Bio-Technology Limited**  
**Fang Haizhou**  
*Executive Director*

Hong Kong, 19 December 2008

## **DIRECTORS OF THE COMPANY**

Executive directors of the Company as at the date of this announcement are Mr Ngiam Mia Je Patrick, Mr Fang Haizhou and Mr Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr Fung Chi Ying, Mr Mauffrey Benoit Jean Marie and Ms Yeow Mee Mooi.

*This announcement for which the directors of Essex Bio-Technology Limited collectively and individually accept full responsibility includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to Essex Bio-Technology Limited. The directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; and (iii) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*

*This announcement will remain on the “Latest Company Announcements” page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least 7 days from the date of its posting and on the website of the Company at [www.essexbio.com](http://www.essexbio.com).*